When we associated thrombocytosis (PLT ≥ 400/nL or PLT ≥ 350/nL) and PLR with a cutoff point of 150.9 to CA125, we observed an enhancement of this clinical value, which was higher than the isolated CA125 clinical value in the range of 15% to 25% risks thresholds. This evidence concerns the gene MUC16 and thrombocytosis disease.